GLP-1s and the Pharmaceutical Industry's Role in Addressing Societal Health Inequities
Original framing: “STAT+: Eli Lilly and the ‘societal obligation’ of GLP-1s” — STAT News
The pharmaceutical industry's focus on GLP-1s is part of a broader historical trend of Western medical dominance. The industry's emphasis on high-value medications reflects a legacy of colonialism and imperialism, where Western medical paradigms were imposed on non-Western cultures. This legacy continues to shape global health policies and reinforce health inequities.
The pharmaceutical industry's emphasis on GLP-1s reflects a narrow focus on disease management, neglecting the importance of prevention, self-care, and social and environmental determinants of health.
This approach exacerbates health inequities, perpetuating the dominance of Western medical paradigms. To address these inequities, we need to develop more inclusive and effective health solutions that prioritize prevention, self-care, and social and environmental determinants of health. This requires a fundamental shift in the pharmaceutical industry's approach, prioritizing access, affordability, and equity. By centering marginalized voices and perspectives, we can develop more effective and inclusive health solutions that address the root causes of health inequities.